CAAN Nursing Practice Guidelines
APPENDIX 1
|
Category
|
Disease
|
Category I
Diseases in which therapeutic apheresis has been shown to be effective.
|
- Myasthenia Gravis (acute exacerbation or pre-thymectomy)
- Eton-Lambert Syndrome
- Coagulation Factor Inhibitors
- Post-Transfusion Purpura
- Refsum's Disease
- Goodpasture's Syndrome
- Autoimmune Haemolytic Anemia(cold antibody type)
- Symptomatic Cryoglobulinemia
- Pemphigus Vulgaris
- Poisoning with Non-Dialysable Protein Bound Toxins
- Sickling Disorders-acute chest syndrome, resistant priapism, stroke(red cell exchange)
- Severe symptomatic thrombocytosis (plateletpheresis)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Plasma Hyperviscosity Syndrome
- Myeloma Kidney (light chain disease)
- Paraprotein Associated Peripheral Neuropathy
- Acute Guillain-Barre Syndrome
- Thrombotic Thrombocytopenic
- Purpura/Haemolytic Uremic Syndrome
|
Category II
Diseases in which the role of therapeutic apheresis is unclear or is under active study.
|
- Systemic Lupus Erythematosus
- Systemic Vasculitis (other than SLE)
- Familial Hypercholesterolemia
- Immune Thrombocytopenic Purpura
- Sezary Syndrome (extracorporeal photopheresis)
- Severe Rh Sensitized Pregnancy
- Peripheral Neuropathy Associated with the Acquired Immune Deficiency Syndrome
|
Category III
Diseases in which therapeutic apheresis has not been shown to be effective.
|
- Multiple Sclerosis
- Renal Transplant Rejection
- Polymyositis/Dermatomyositis
- Amyotrophic Lateral Sclerosis
- Fulminant Hepatic Failure
- Schizophrenia
- Idiopathic Rapidly Progressive Glomerulonephritis
|
